Topic

Articles

Pfizer and Gero have partnered to discover potential therapeutic targets for fibrotic diseases using machine learning technology.

Pfizer and Gero Form Collaboration to Discover Potential Targets for Fibrotic Diseases

The collaboration between AbbVie and Anima Biotech will combine Anima's mRNA Lightning technology platform with AbbVie's extensive expertise in oncology and immunology.

AbbVie and Anima Biotech Partner on Discovery and Development of mRNA Biology Modulators

The definitive agreement will give AstraZeneca global rights to CinCor’s portfolio of cardiorenal disease treatments.

AstraZeneca Inks $1.8 Billion Acquisition for CinCor Pharma

Ipsen’s $952 million acquisition of Albireo is designed to bolster the company's rare disease portfolio.

Ipsen to Bolster Liver Disease Portfolio with Albireo Acquisition

Sartorius and RoosterBio will work together to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies.

Sartorius and RoosterBio Strike Downstream Collaboration Deal

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Messenger RNA is inherently unstable and thus requires unique solutions to protect its cohesion.

Finding Solutions to Manage mRNA Instability

Astrea Bioseparations has acquired Delta Precision, a manufacturer of chromatography columns for biomanufacturing.

Astrea Bioseparations Acquires Delta Precision

Avantor and Catalent have entered into a multi-year supply and services agreement. 

Avantor and Catalent Enter Multi-Year Agreement

Agilent’s acquisition of Avida grants them access to high-performance enrichment workflows that enable NGS approaches for studying cancer.

Agilent Acquires Life Sciences Company Avida Biomed

Merck, known as MSD outside of the United States and Canada, will pay Kelun-Biotech up to $9l3 billion for seven early-stage oncology treatments.

BioBusiness